Business UpdateJun 16, 2026, 07:26 AM
Avalo Therapeutics Advances AVTX-010 Pipeline Candidate
AI Summary
Avalo Therapeutics, Inc. announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody, with plans for Investigational New Drug (IND) submission in the first half of 2027. The company also posted an updated investor presentation. This news follows positive topline data from their Phase 2 LOTUS study for abdakibart in moderate-to-severe hidradenitis suppurativa (HS).
Key Highlights
- Avalo Therapeutics announced advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody.
- AVTX-010 has potential for development in hidradenitis suppurativa (HS) and other inflammatory disorders.
- Investigational New Drug (IND) submission for AVTX-010 is planned for the first half of 2027.
- The company posted an updated investor presentation on its website.
- Avalo Therapeutics reported positive topline data for abdakibart in a Phase 2 clinical trial for HS.
Price Impact
More from AVTX